Discrepancies between osteoporotic fracture evaluations in men based on German (DVO) osteoporosis guidelines or the FRAX score

2023 | journal article. A publication with affiliation to the University of Göttingen.

Jump to: Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​Discrepancies between osteoporotic fracture evaluations in men based on German (DVO) osteoporosis guidelines or the FRAX score​
Witzel, J. C.; Giessel, A.; Heppner, C.; Lamersdorf, A.; Leha, A.; Glueer, C. & Siggelkow, H.​ (2023) 
Experimental and Clinical Endocrinology & Diabetes,.​ DOI: https://doi.org/10.1055/a-1977-4413 

Documents & Media

document.pdf393.88 kBAdobe PDF

License

GRO License GRO License

Details

Authors
Witzel, Judith Charlotte; Giessel, Anna; Heppner, Christina; Lamersdorf, Annette; Leha, Andreas; Glueer, Claus; Siggelkow, Heide
Abstract
Introduction: Established scores estimate 10-year fracture risk in osteoporosis to assist with treatment recommendations. This study compares and contrasts the risk probabilities of major osteoporotic and hip fractures calculated by the FRAX tool with those of the DVO score, established in German-speaking countries. Material and methods: This seven-year retrospective study analyzes data of 125 male patients (mean age: 59.2±10.7 years) evaluated for osteoporosis. For the DVO score, the therapy threshold of >30% for vertebral and hip fractures suggested by DVO guidelines was implemented. We calculated fracture risks based on FRAX scores with aBMD and applied a common therapy threshold of ≥3% for hip fracture and subsequently determined the “DVO-equivalent risk level” for FRAX-based assessment that would identify as many male patients as identified by the DVO score. Results: Based on DVO score, 60.0% of patients had a 10-year risk of hip and vertebral fractures >30%. The recommendations for individuals based on FRAX scores for hip fracture with aBMD with risk ≥ 3% overlapped with those based on DVO score in 40.8% of patients. Patients identified for treatment only by DVO score presented a higher percentage of spine fractures (65% vs. 41%). The thresholds for this “DVO-equivalent risk level” for ‘FRAX with aBMD’ would be ≥ 6.9% for MOF and ≥ 2.1% for HF. This study demonstrates that the DVO score was more sensitive than the FRAX score for patients with spinal fractures. We suggest considering the appropriate score and therapy threshold carefully in the daily care of male patients.
Issue Date
2023
Journal
Experimental and Clinical Endocrinology & Diabetes 
ISSN
0947-7349
eISSN
1439-3646
Language
English

Reference

Citations


Social Media